{"pmid":32379723,"title":"Molecular detection of SARS-CoV-2 in formalin fixed paraffin embedded specimens.","text":["Molecular detection of SARS-CoV-2 in formalin fixed paraffin embedded specimens.","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of human coronavirus disease 2019 (COVID-19), emerged in Wuhan, China in December 2019. The virus rapidly spread globally, resulting in a public-health crisis including more than 3.1 million cases and 224,000 deaths as of May 1, 2020. Here, we describe the identification and evaluation of commercially available reagents and assays for the molecular detection of SARS-CoV-2 in infected formalin fixed paraffin embedded (FFPE) cell pellets. We identified a suitable rabbit polyclonal anti-SARS-CoV spike protein antibody and a mouse monoclonal anti-SARS-CoV nucleocapsid protein (NP) antibody for cross detection of the respective SARS-CoV-2 proteins by immunohistochemistry (IHC) and immunofluorescence assay (IFA). Next, we established RNAscope in situ hybridization (ISH) to detect SARS-CoV-2 RNA. Furthermore, we established a multiplex fluorescence ISH (mFISH) to detect positive-sense SARS-CoV-2 RNA and negative-sense SARS-CoV-2 RNA (a replicative intermediate indicating viral replication). Finally, we developed a dual staining assay using IHC and ISH to detect SARS-CoV-2 antigen and RNA in the same FFPE section. These reagents and assays will accelerate COVID-19 pathogenesis studies in humans and in COVID-19 animal models.","JCI Insight","Liu, Jun","Babka, April M","Kearney, Brian J","Radoshitzky, Sheli R","Kuhn, Jens H","Zeng, Xiankun","32379723"],"abstract":["Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of human coronavirus disease 2019 (COVID-19), emerged in Wuhan, China in December 2019. The virus rapidly spread globally, resulting in a public-health crisis including more than 3.1 million cases and 224,000 deaths as of May 1, 2020. Here, we describe the identification and evaluation of commercially available reagents and assays for the molecular detection of SARS-CoV-2 in infected formalin fixed paraffin embedded (FFPE) cell pellets. We identified a suitable rabbit polyclonal anti-SARS-CoV spike protein antibody and a mouse monoclonal anti-SARS-CoV nucleocapsid protein (NP) antibody for cross detection of the respective SARS-CoV-2 proteins by immunohistochemistry (IHC) and immunofluorescence assay (IFA). Next, we established RNAscope in situ hybridization (ISH) to detect SARS-CoV-2 RNA. Furthermore, we established a multiplex fluorescence ISH (mFISH) to detect positive-sense SARS-CoV-2 RNA and negative-sense SARS-CoV-2 RNA (a replicative intermediate indicating viral replication). Finally, we developed a dual staining assay using IHC and ISH to detect SARS-CoV-2 antigen and RNA in the same FFPE section. These reagents and assays will accelerate COVID-19 pathogenesis studies in humans and in COVID-19 animal models."],"journal":"JCI Insight","authors":["Liu, Jun","Babka, April M","Kearney, Brian J","Radoshitzky, Sheli R","Kuhn, Jens H","Zeng, Xiankun"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32379723","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1172/jci.insight.139042","keywords":["covid-19","molecular diagnosis","molecular pathology","virology"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Paraffin","Formaldehyde"],"topics":["Diagnosis"],"weight":1,"_version_":1666597097288237056,"score":9.490897,"similar":[{"pmid":32366599,"title":"SARS-CoV-2 detection in formalin-fixed paraffin-embedded tissue specimens from surgical resection of tongue squamous cell carcinoma.","text":["SARS-CoV-2 detection in formalin-fixed paraffin-embedded tissue specimens from surgical resection of tongue squamous cell carcinoma.","In the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, pathologists can be exposed to infection handling surgical specimens. Guidelines related to safety procedures in the laboratory have been released. However, there is a lack of studies performed on biopsy and surgical resection specimens. Here we report the detection of SARS-CoV-2 in formalin-fixed paraffin-embedded samples from surgical resection of tongue squamous cell carcinoma of a patient who developed COVID-19 postsurgery. RNA of SARS-CoV-2 strain was detected in the tumour and the normal submandibular gland samples using real-time PCR-based assay. No viral RNA was found in metastatic and reactive lymph nodes. We demonstrated that SARS-CoV-2 RNA can be detected in routine histopathological samples even before COVID-19 disease development. These findings may give important information on the possible sites of infection or virus reservoir, and highlight the necessity of proper handling and fixation before sample processing.","J Clin Pathol","Guerini-Rocco, Elena","Taormina, Sergio Vincenzo","Vacirca, Davide","Ranghiero, Alberto","Rappa, Alessandra","Fumagalli, Caterina","Maffini, Fausto","Rampinelli, Cristiano","Galetta, Domenico","Tagliabue, Marta","Ansarin, Mohssen","Barberis, Massimo","32366599"],"abstract":["In the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, pathologists can be exposed to infection handling surgical specimens. Guidelines related to safety procedures in the laboratory have been released. However, there is a lack of studies performed on biopsy and surgical resection specimens. Here we report the detection of SARS-CoV-2 in formalin-fixed paraffin-embedded samples from surgical resection of tongue squamous cell carcinoma of a patient who developed COVID-19 postsurgery. RNA of SARS-CoV-2 strain was detected in the tumour and the normal submandibular gland samples using real-time PCR-based assay. No viral RNA was found in metastatic and reactive lymph nodes. We demonstrated that SARS-CoV-2 RNA can be detected in routine histopathological samples even before COVID-19 disease development. These findings may give important information on the possible sites of infection or virus reservoir, and highlight the necessity of proper handling and fixation before sample processing."],"journal":"J Clin Pathol","authors":["Guerini-Rocco, Elena","Taormina, Sergio Vincenzo","Vacirca, Davide","Ranghiero, Alberto","Rappa, Alessandra","Fumagalli, Caterina","Maffini, Fausto","Rampinelli, Cristiano","Galetta, Domenico","Tagliabue, Marta","Ansarin, Mohssen","Barberis, Massimo"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32366599","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1136/jclinpath-2020-206635","keywords":["pathology, molecular","pathology, oral","viruses"],"e_drugs":["Formaldehyde","Paraffin"],"topics":["Diagnosis"],"weight":1,"_version_":1666138496183566337,"score":419.28552},{"pmid":32451533,"title":"Molecular Detection of SARS-CoV-2 Infection in FFPE Samples and Histopathologic Findings in Fatal SARS-CoV-2 Cases.","text":["Molecular Detection of SARS-CoV-2 Infection in FFPE Samples and Histopathologic Findings in Fatal SARS-CoV-2 Cases.","OBJECTIVES: To report methods and findings of 2 autopsies with molecular evaluation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positive individuals. METHODS: Postmortem examination was completed following Centers for Disease Control and Prevention public guidelines. Numerous formalin-fixed paraffin-embedded (FFPE) tissue types from each case were surveyed for SARS-CoV-2 RNA by quantitative reverse transcription polymerase chain reaction (qRT-PCR). SARS-CoV-2 viral genome was sequenced by next-generation sequencing (NGS) from FFPE lung tissue blocks. RESULTS: Postmortem examinations revealed diffuse alveolar damage, while no viral-associated hepatic, cardiac, or renal damage was observed. Viral RNA was detected in lungs, bronchi, lymph nodes, and spleen in both cases using qRT-PCR method. RNA sequencing using NGS in case 1 revealed mutations most consistent with Western European Clade A2a with ORF1a L3606F mutation. CONCLUSIONS: SARS-CoV-2 testing and viral sequencing can be performed from FFPE tissue. Detection and sequencing of SARS-CoV-2 in combination with morphological findings from postmortem tissue examination can aid in gaining a better understanding of the virus's pathophysiologic effects on human health.","Am J Clin Pathol","Sekulic, Miroslav","Harper, Holly","Nezami, Behtash G","Shen, Daniel L","Sekulic, Simona Pichler","Koeth, Aaron T","Harding, Clifford V","Gilmore, Hannah","Sadri, Navid","32451533"],"abstract":["OBJECTIVES: To report methods and findings of 2 autopsies with molecular evaluation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positive individuals. METHODS: Postmortem examination was completed following Centers for Disease Control and Prevention public guidelines. Numerous formalin-fixed paraffin-embedded (FFPE) tissue types from each case were surveyed for SARS-CoV-2 RNA by quantitative reverse transcription polymerase chain reaction (qRT-PCR). SARS-CoV-2 viral genome was sequenced by next-generation sequencing (NGS) from FFPE lung tissue blocks. RESULTS: Postmortem examinations revealed diffuse alveolar damage, while no viral-associated hepatic, cardiac, or renal damage was observed. Viral RNA was detected in lungs, bronchi, lymph nodes, and spleen in both cases using qRT-PCR method. RNA sequencing using NGS in case 1 revealed mutations most consistent with Western European Clade A2a with ORF1a L3606F mutation. CONCLUSIONS: SARS-CoV-2 testing and viral sequencing can be performed from FFPE tissue. Detection and sequencing of SARS-CoV-2 in combination with morphological findings from postmortem tissue examination can aid in gaining a better understanding of the virus's pathophysiologic effects on human health."],"journal":"Am J Clin Pathol","authors":["Sekulic, Miroslav","Harper, Holly","Nezami, Behtash G","Shen, Daniel L","Sekulic, Simona Pichler","Koeth, Aaron T","Harding, Clifford V","Gilmore, Hannah","Sadri, Navid"],"date":"2020-05-27T11:00:00Z","year":2020,"_id":"32451533","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1093/ajcp/aqaa091","keywords":["autopsy","covid-19","ffpe","molecular testing","sars-cov-2; coronavirus","viral sequencing","ncov-19"],"locations":["bronchi"],"e_drugs":["Paraffin","Formaldehyde"],"topics":["Mechanism","Diagnosis"],"weight":1,"_version_":1667881798526304256,"score":335.1339},{"pmid":32427334,"title":"Detection of Nucleocapsid Antibody to SARS-CoV-2 is More Sensitive than Antibody to Spike Protein in COVID-19 Patients.","text":["Detection of Nucleocapsid Antibody to SARS-CoV-2 is More Sensitive than Antibody to Spike Protein in COVID-19 Patients.","BACKGROUND: SARS-CoV-2, the cause of coronavirus disease 2019 (COVID-19), is associated with respiratory-related morbidity and mortality. Assays to detect virus-specific antibodies are important to understand the prevalence of infection and the course of the immune response. METHODOLOGY: Quantitative measurements of plasma or serum antibodies by luciferase immunoprecipitation assay systems (LIPS) to the nucleocapsid and spike proteins were analyzed in 100 cross-sectional or longitudinal samples from SARS-CoV-2-infected patients. A subset of samples was tested with and without heat inactivation. RESULTS: Fifteen or more days after symptom onset, antibodies against SARS-CoV-2 nucleocapsid protein showed 100% sensitivity and 100% specificity, while antibodies to spike protein were detected with 91% sensitivity and 100% specificity. Neither antibody levels nor the rate of seropositivity were significantly reduced by heat inactivation of samples. Analysis of daily samples from six patients with COVID-19 showed anti-nucleocapsid and spike antibodies appearing between day 8 and day 14 after initial symptoms. Immunocompromised patients generally had a delayed antibody response to SARS-CoV-2 compared to immunocompetent patients. CONCLUSIONS: Antibody to the nucleocapsid protein of SARS-CoV-2 is more sensitive than spike protein antibody for detecting early infection. Analyzing heat-inactivated samples by LIPS is a safe and sensitive method for detecting SARS-CoV-2 antibodies.","J Infect Dis","Burbelo, Peter D","Riedo, Francis X","Morishima, Chihiro","Rawlings, Stephen","Smith, Davey","Das, Sanchita","Strich, Jeffrey R","Chertow, Daniel S","Davey, Richard T","Cohen, Jeffrey I","32427334"],"abstract":["BACKGROUND: SARS-CoV-2, the cause of coronavirus disease 2019 (COVID-19), is associated with respiratory-related morbidity and mortality. Assays to detect virus-specific antibodies are important to understand the prevalence of infection and the course of the immune response. METHODOLOGY: Quantitative measurements of plasma or serum antibodies by luciferase immunoprecipitation assay systems (LIPS) to the nucleocapsid and spike proteins were analyzed in 100 cross-sectional or longitudinal samples from SARS-CoV-2-infected patients. A subset of samples was tested with and without heat inactivation. RESULTS: Fifteen or more days after symptom onset, antibodies against SARS-CoV-2 nucleocapsid protein showed 100% sensitivity and 100% specificity, while antibodies to spike protein were detected with 91% sensitivity and 100% specificity. Neither antibody levels nor the rate of seropositivity were significantly reduced by heat inactivation of samples. Analysis of daily samples from six patients with COVID-19 showed anti-nucleocapsid and spike antibodies appearing between day 8 and day 14 after initial symptoms. Immunocompromised patients generally had a delayed antibody response to SARS-CoV-2 compared to immunocompetent patients. CONCLUSIONS: Antibody to the nucleocapsid protein of SARS-CoV-2 is more sensitive than spike protein antibody for detecting early infection. Analyzing heat-inactivated samples by LIPS is a safe and sensitive method for detecting SARS-CoV-2 antibodies."],"journal":"J Infect Dis","authors":["Burbelo, Peter D","Riedo, Francis X","Morishima, Chihiro","Rawlings, Stephen","Smith, Davey","Das, Sanchita","Strich, Jeffrey R","Chertow, Daniel S","Davey, Richard T","Cohen, Jeffrey I"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32427334","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1093/infdis/jiaa273","keywords":["covid-19","sars-cov-2","coronavirus","serology"],"topics":["Diagnosis"],"weight":1,"_version_":1667352728788008960,"score":269.56476},{"pmid":32306853,"title":"Development of a reverse transcription-loop-mediated isothermal amplification as a rapid early-detection method for novel SARS-CoV-2.","text":["Development of a reverse transcription-loop-mediated isothermal amplification as a rapid early-detection method for novel SARS-CoV-2.","The previous outbreaks of SARS-CoV and MERS-CoV have led researchers to study the role of diagnostics in impediment of further spread and transmission. With the recent emergence of the novel SARS-CoV-2, the availability of rapid, sensitive, and reliable diagnostic methods is essential for disease control. Hence, we have developed a reverse transcription loop-mediated isothermal amplification (RT-LAMP) assay for the specific detection of SARS-CoV-2. The primer sets for RT-LAMP assay were designed to target the nucleocapsid gene of the viral RNA, and displayed a detection limit of 10(2) RNA copies close to that of qRT-PCR. Notably, the assay has exhibited a rapid detection span of 30 min combined with the colorimetric visualization. This test can detect specifically viral RNAs of the SARS-CoV-2 with no cross-reactivity to related coronaviruses, such as HCoV-229E, HCoV-NL63, HCoV-OC43, and MERS-CoV as well as human infectious influenza viruses (type B, H1N1pdm, H3N2, H5N1, H5N6, H5N8, and H7N9), and other respiratory disease-causing viruses (RSVA, RSVB, ADV, PIV, MPV, and HRV). Furthermore, the developed RT-LAMP assay has been evaluated using specimens collected from COVID-19 patients that exhibited high agreement to the qRT-PCR. Our RT-LAMP assay is simple to perform, less expensive, time-efficient, and can be used in clinical laboratories for preliminary detection of SARS-CoV-2 in suspected patients. In addition to the high sensitivity and specificity, this isothermal amplification conjugated with a single-tube colorimetric detection method may contribute to the public health responses and disease control, especially in the areas with limited laboratory capacities.","Emerg Microbes Infect","Baek, Yun Hee","Um, Jihye","Antigua, Khristine Joy C","Park, Ji-Hyun","Kim, Yeonjae","Oh, Sol","Kim, Young-Il","Choi, Won-Suk","Kim, Seong Gyu","Jeong, Ju Hwan","Chin, Bum Sik","Nicolas, Halcyon Dawn G","Ahn, Ji-Young","Shin, Kyeong Seob","Choi, Young Ki","Park, Jun-Sun","Song, Min-Suk","32306853"],"abstract":["The previous outbreaks of SARS-CoV and MERS-CoV have led researchers to study the role of diagnostics in impediment of further spread and transmission. With the recent emergence of the novel SARS-CoV-2, the availability of rapid, sensitive, and reliable diagnostic methods is essential for disease control. Hence, we have developed a reverse transcription loop-mediated isothermal amplification (RT-LAMP) assay for the specific detection of SARS-CoV-2. The primer sets for RT-LAMP assay were designed to target the nucleocapsid gene of the viral RNA, and displayed a detection limit of 10(2) RNA copies close to that of qRT-PCR. Notably, the assay has exhibited a rapid detection span of 30 min combined with the colorimetric visualization. This test can detect specifically viral RNAs of the SARS-CoV-2 with no cross-reactivity to related coronaviruses, such as HCoV-229E, HCoV-NL63, HCoV-OC43, and MERS-CoV as well as human infectious influenza viruses (type B, H1N1pdm, H3N2, H5N1, H5N6, H5N8, and H7N9), and other respiratory disease-causing viruses (RSVA, RSVB, ADV, PIV, MPV, and HRV). Furthermore, the developed RT-LAMP assay has been evaluated using specimens collected from COVID-19 patients that exhibited high agreement to the qRT-PCR. Our RT-LAMP assay is simple to perform, less expensive, time-efficient, and can be used in clinical laboratories for preliminary detection of SARS-CoV-2 in suspected patients. In addition to the high sensitivity and specificity, this isothermal amplification conjugated with a single-tube colorimetric detection method may contribute to the public health responses and disease control, especially in the areas with limited laboratory capacities."],"journal":"Emerg Microbes Infect","authors":["Baek, Yun Hee","Um, Jihye","Antigua, Khristine Joy C","Park, Ji-Hyun","Kim, Yeonjae","Oh, Sol","Kim, Young-Il","Choi, Won-Suk","Kim, Seong Gyu","Jeong, Ju Hwan","Chin, Bum Sik","Nicolas, Halcyon Dawn G","Ahn, Ji-Young","Shin, Kyeong Seob","Choi, Young Ki","Park, Jun-Sun","Song, Min-Suk"],"date":"2020-04-21T11:00:00Z","year":2020,"_id":"32306853","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1080/22221751.2020.1756698","keywords":["covid-19","sars-cov-2","colorimetric detection","molecular diagnosis","novel coronavirus","reverse transcription-loop-mediated isothermal amplification"],"topics":["Diagnosis"],"weight":1,"_version_":1666138491234287617,"score":267.21243},{"pmid":32323974,"pmcid":"PMC7202245","title":"Rapid and Sensitive Detection of anti-SARS-CoV-2 IgG, Using Lanthanide-Doped Nanoparticles-Based Lateral Flow Immunoassay.","text":["Rapid and Sensitive Detection of anti-SARS-CoV-2 IgG, Using Lanthanide-Doped Nanoparticles-Based Lateral Flow Immunoassay.","The outbreak of 2019 coronavirus disease (COVID-19) has been a challenge for hospital laboratories because of the huge number of samples that must be tested for the presence of the causative pathogen, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Simple and rapid immunodiagnostic methods are urgently needed to identify positive cases. Here we report the development of a rapid and sensitive lateral flow immunoassay (LFIA) that uses lanthanide-doped polysterene nanoparticles (LNPs) to detect anti-SARV-CoV-2 IgG in human serum. A recombinant nucleocapsid phosphoprotein of SARS-CoV-2 was dispensed onto a nitrocellulose membrane to capture specific IgG. Mouse anti-human IgG antibody was labeled with self-assembled LNPs that served as a fluorescent reporter. A 100-muL aliquot of serum samples (1:1000 dilution) was used for this assay and the whole detection process took 10 min. The results of the validation experiment met the requirements for clinical diagnostic reagents. A value of 0.0666 was defined as the cutoff value by assaying 51 normal samples. We tested 7 samples that were positive by reverse-transcription (RT-)PCR and 12 that were negative but clinically suspicious for the presence of anti-SARS-CoV-2 IgG. One of the negative samples was determined to be SARS-CoV-2 IgG positive, while the results for the other samples were consistent with those obtained by RT-PCR. Thus, this assay can achieve rapid and sensitive detection of anti-SARS-CoV-2 IgG in human serum and allow positive identification in suspicious cases; it can also be useful for monitoring the progression COVID-19 and evaluating patients' response to treatment.","Anal Chem","Chen, Zhenhua","Zhang, Zhigao","Zhai, Xiangming","Li, Yongyin","Lin, Li","Zhao, Hui","Bian, Lun","Li, Peng","Yu, Lei","Wu, Yingsong","Lin, Guanfeng","32323974"],"abstract":["The outbreak of 2019 coronavirus disease (COVID-19) has been a challenge for hospital laboratories because of the huge number of samples that must be tested for the presence of the causative pathogen, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Simple and rapid immunodiagnostic methods are urgently needed to identify positive cases. Here we report the development of a rapid and sensitive lateral flow immunoassay (LFIA) that uses lanthanide-doped polysterene nanoparticles (LNPs) to detect anti-SARV-CoV-2 IgG in human serum. A recombinant nucleocapsid phosphoprotein of SARS-CoV-2 was dispensed onto a nitrocellulose membrane to capture specific IgG. Mouse anti-human IgG antibody was labeled with self-assembled LNPs that served as a fluorescent reporter. A 100-muL aliquot of serum samples (1:1000 dilution) was used for this assay and the whole detection process took 10 min. The results of the validation experiment met the requirements for clinical diagnostic reagents. A value of 0.0666 was defined as the cutoff value by assaying 51 normal samples. We tested 7 samples that were positive by reverse-transcription (RT-)PCR and 12 that were negative but clinically suspicious for the presence of anti-SARS-CoV-2 IgG. One of the negative samples was determined to be SARS-CoV-2 IgG positive, while the results for the other samples were consistent with those obtained by RT-PCR. Thus, this assay can achieve rapid and sensitive detection of anti-SARS-CoV-2 IgG in human serum and allow positive identification in suspicious cases; it can also be useful for monitoring the progression COVID-19 and evaluating patients' response to treatment."],"journal":"Anal Chem","authors":["Chen, Zhenhua","Zhang, Zhigao","Zhai, Xiangming","Li, Yongyin","Lin, Li","Zhao, Hui","Bian, Lun","Li, Peng","Yu, Lei","Wu, Yingsong","Lin, Guanfeng"],"date":"2020-04-24T11:00:00Z","year":2020,"_id":"32323974","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1021/acs.analchem.0c00784","locations":["Mouse"],"e_drugs":["Lanthanoid Series Elements"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1666138493813784576,"score":263.95932}]}